Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2022

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

ASH 2022: Multiple myeloma roundup

Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA

ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...

Dr Monzr Al Malki - City of Hope, Duarte, USA

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease ( Dr Monzr Al Malki - City of Hope, Duarte, USA )

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA

Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R...

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients...

Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib ( Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA )

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients...

Dr Mark Litzow - Mayo Clinic, Rochester, USA

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Dr Shernan Holtan - University of Minnesota, Minneapolis, USA

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response...

Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )

An analysis of the worldwide utilisation of haematopoietic stem cell...

Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA

An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia ( Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA )

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows...

Dr Emma Searle - University of Manchester, Manchester, UK

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )

More from ecancer